Corporate social responsibility on hold when it comes to outrageous drug prices
Imagine you just went to your local pharmacy and were told that the cost of a life-saving drug was $22,500 for 30 tablets to treat AIDS or another infectious disease. Well, if you need the drug Daraprim, that is what you would have to pay. Turing Pharmaceuticals purchased the right to Darprim this past August Read More →
Read More →European regulators approve Amgen cancer drug Kyprolis
Thousand Oaks-based Amgen scored another major victory Nov. 19. European regulators approved experimental drug Kyprolis on Thursday for patients who have received at least one prior treatment for multiple-myeloma. Kyprolis was the cornerstone of Amgen’s $10.4 billion buyout of Onyx Pharmaceuticals in 2013. Multiple-myeloma is a form of blood cancer that forms in plasma cells Read More →
Read More →French Hospital Medical Center unveils educational facility
French Hospital Medical Center has taken the wraps off an 18,000-square-foot health and education facility it hopes will forge closer ties between the hospital and higher education in San Luis Obispo. With about 200 business and community leaders standing by, CEO Alan Iftinik unveiled the Copeland Health Education Pavilion. Iftinik said the building, which Read More →
Read More →Goleta-based Sientra’s third quarter revenues down
Sientra Inc. sales were down 6.9 percent in the third quarter of 2015 but the results were largely unaffected by recent pandemonium at the company. The Goleta-based company reported third quarter results on Nov. 16 for the quarter that ended on Sept. 30, just one week after European regulators pulled products made by Sientra’s Brazilian Read More →
Read More →Goleta breast implant maker Sientra shakes up C-Suite
The writing was on the wall at Sientra. On Nov. 12, the company’s top executives took the fall. The embattled Goleta-based breast implant manufacturer cleaned house Thursday afternoon. Sientra founder and CEO Hani Zeini stepped down as CEO and he will be replaced by industry veteran Jeffrey Nugent. Nicholas Simon also resigned as chairman Read More →
Read More →Inogen’s third quarter earnings beat Wall Street expectations
Inogen, a Goleta-based maker of direct-to-consumer respiratory products, beat analyst estimates for revenue when the company released third quarter earnings on Nov. 10. Revenues were up 38.7 percent from $29.4 million during the third quarter of last year to $40.8 million this year. Analysts had predicted revenues of $37 million. Inogen also reported adjusted Read More →
Read More →FDA to review Amgen’s new kidney disease dug
Thousand Oaks-based biotech giant Amgen announced on Nov. 6 that the Food and Drug Administration will review a new treatment for patients with chronic kidney disease. The new drug, Etelcalcetide, works by suppressing the secretion of a parathyroid hormone. The drug is administered intravenously three times per week at the end of a dialysis session. Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
